-
How important are willingness to participate studies in encouraging patient enrollment in oncology trials?
Anand Shah
Editorial: Clinical Investigation
-
How important are willingness to participate studies in encouraging patient enrollment in oncology trials?
Anand Shah
Editorial: Clinical Investigation
-
How important are willingness to participate studies in encouraging patient enrollment in oncology trials?
Anand Shah
Editorial: Clinical Investigation
-
How important are willingness to participate studies in encouraging patient enrollment in oncology trials?
Anand Shah
Editorial: Clinical Investigation
-
How important are willingness to participate studies in encouraging patient enrollment in oncology trials?
Anand Shah
Editorial: Clinical Investigation
-
How important are willingness to participate studies in encouraging patient enrollment in oncology trials?
Anand Shah
Editorial: Clinical Investigation
-
Novel therapeutics for cystic fibrosis: what does the future hold?
Carlos E Milla
Editorial: Clinical Investigation
-
Novel therapeutics for cystic fibrosis: what does the future hold?
Carlos E Milla
Editorial: Clinical Investigation
-
Novel therapeutics for cystic fibrosis: what does the future hold?
Carlos E Milla
Editorial: Clinical Investigation
-
Novel therapeutics for cystic fibrosis: what does the future hold?
Carlos E Milla
Editorial: Clinical Investigation
-
Novel therapeutics for cystic fibrosis: what does the future hold?
Carlos E Milla
Editorial: Clinical Investigation
-
Novel therapeutics for cystic fibrosis: what does the future hold?
Carlos E Milla
Editorial: Clinical Investigation
-
Comprehensive and effective system of standard operating procedures for investigator-initiated trials
Heike Moenkemann, Rita Pilger, Sylvia Reinecker, Peggy Houben & Ursula Paulu
Special Report: Clinical Investigation
-
Comprehensive and effective system of standard operating procedures for investigator-initiated trials
Heike Moenkemann, Rita Pilger, Sylvia Reinecker, Peggy Houben & Ursula Paulu
Special Report: Clinical Investigation
-
Comprehensive and effective system of standard operating procedures for investigator-initiated trials
Heike Moenkemann, Rita Pilger, Sylvia Reinecker, Peggy Houben & Ursula Paulu
Special Report: Clinical Investigation
-
Comprehensive and effective system of standard operating procedures for investigator-initiated trials
Heike Moenkemann, Rita Pilger, Sylvia Reinecker, Peggy Houben & Ursula Paulu
Special Report: Clinical Investigation
-
Comprehensive and effective system of standard operating procedures for investigator-initiated trials
Heike Moenkemann, Rita Pilger, Sylvia Reinecker, Peggy Houben & Ursula Paulu
Special Report: Clinical Investigation
-
Comprehensive and effective system of standard operating procedures for investigator-initiated trials
Heike Moenkemann, Rita Pilger, Sylvia Reinecker, Peggy Houben & Ursula Paulu
Special Report: Clinical Investigation
-
Estimating site costs prior to conducting clinical trials
Dorothee Arenz, Barbara Hero, Barbara F Eichhorst, Martin Langer, Lars Pester, Julia von Tresckow, Jrg J Vehreschild, Maria JGT Vehreschild, Oliver A Cornely
Special Report: Clinical Investigation
-
Estimating site costs prior to conducting clinical trials
Dorothee Arenz, Barbara Hero, Barbara F Eichhorst, Martin Langer, Lars Pester, Julia von Tresckow, Jrg J Vehreschild, Maria JGT Vehreschild, Oliver A Cornely
Special Report: Clinical Investigation
-
Estimating site costs prior to conducting clinical trials
Dorothee Arenz, Barbara Hero, Barbara F Eichhorst, Martin Langer, Lars Pester, Julia von Tresckow, Jrg J Vehreschild, Maria JGT Vehreschild, Oliver A Cornely
Special Report: Clinical Investigation
-
Estimating site costs prior to conducting clinical trials
Dorothee Arenz, Barbara Hero, Barbara F Eichhorst, Martin Langer, Lars Pester, Julia von Tresckow, Jrg J Vehreschild, Maria JGT Vehreschild, Oliver A Cornely
Special Report: Clinical Investigation
-
Estimating site costs prior to conducting clinical trials
Dorothee Arenz, Barbara Hero, Barbara F Eichhorst, Martin Langer, Lars Pester, Julia von Tresckow, Jrg J Vehreschild, Maria JGT Vehreschild, Oliver A Cornely
Special Report: Clinical Investigation
-
Estimating site costs prior to conducting clinical trials
Dorothee Arenz, Barbara Hero, Barbara F Eichhorst, Martin Langer, Lars Pester, Julia von Tresckow, Jrg J Vehreschild, Maria JGT Vehreschild, Oliver A Cornely
Special Report: Clinical Investigation
-
The Scottish Childrens Research Network: challenges, opportunities and achievements
Peter J Helms, Pamela Dicks
Research Update: Clinical Investigation
-
The Scottish Childrens Research Network: challenges, opportunities and achievements
Peter J Helms, Pamela Dicks
Research Update: Clinical Investigation
-
The Scottish Childrens Research Network: challenges, opportunities and achievements
Peter J Helms, Pamela Dicks
Research Update: Clinical Investigation
-
The Scottish Childrens Research Network: challenges, opportunities and achievements
Peter J Helms, Pamela Dicks
Research Update: Clinical Investigation
-
The Scottish Childrens Research Network: challenges, opportunities and achievements
Peter J Helms, Pamela Dicks
Research Update: Clinical Investigation
-
The Scottish Childrens Research Network: challenges, opportunities and achievements
Peter J Helms, Pamela Dicks
Research Update: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
How will the reporting recommendations for tumor marker prognostic studies affect clinical trials?
Sheila E Taube, Daniel F Hayes
Editorial: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Emilio Perucca
Emilio Perucca
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Emilio Perucca
Emilio Perucca
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Emilio Perucca
Emilio Perucca
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Emilio Perucca
Emilio Perucca
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Emilio Perucca
Emilio Perucca
Interview: Clinical Investigation
-
Why are epilepsy trials failing? Interview with Emilio Perucca
Emilio Perucca
Interview: Clinical Investigation
-
Challenges in the clinical development of stem cell therapy
Natasa Levicar, Nagy A Habib
Editorial: Clinical Investigation
-
Challenges in the clinical development of stem cell therapy
Natasa Levicar, Nagy A Habib
Editorial: Clinical Investigation
-
Challenges in the clinical development of stem cell therapy
Natasa Levicar, Nagy A Habib
Editorial: Clinical Investigation
-
Challenges in the clinical development of stem cell therapy
Natasa Levicar, Nagy A Habib
Editorial: Clinical Investigation
-
Challenges in the clinical development of stem cell therapy
Natasa Levicar, Nagy A Habib
Editorial: Clinical Investigation
-
Challenges in the clinical development of stem cell therapy
Natasa Levicar, Nagy A Habib
Editorial: Clinical Investigation
-
New considerations in the design of clinical trials for the treatment of acute leukemia
Christopher S Hourigan, Judith E Karp
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for the treatment of acute leukemia
Christopher S Hourigan, Judith E Karp
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for the treatment of acute leukemia
Christopher S Hourigan, Judith E Karp
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for the treatment of acute leukemia
Christopher S Hourigan, Judith E Karp
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for the treatment of acute leukemia
Christopher S Hourigan, Judith E Karp
Review Article: Clinical Investigation
-
New considerations in the design of clinical trials for the treatment of acute leukemia
Christopher S Hourigan, Judith E Karp
Review Article: Clinical Investigation
-
New therapeutics for pulmonary arterial hypertension: do gene therapies have translational values?
Roxane Paulin, Marjorie Barrier, Sebastien Bonnet
Editorial: Clinical Investigation
-
New therapeutics for pulmonary arterial hypertension: do gene therapies have translational values?
Roxane Paulin, Marjorie Barrier, Sebastien Bonnet
Editorial: Clinical Investigation
-
New therapeutics for pulmonary arterial hypertension: do gene therapies have translational values?
Roxane Paulin, Marjorie Barrier, Sebastien Bonnet
Editorial: Clinical Investigation
-
New therapeutics for pulmonary arterial hypertension: do gene therapies have translational values?
Roxane Paulin, Marjorie Barrier, Sebastien Bonnet
Editorial: Clinical Investigation
-
New therapeutics for pulmonary arterial hypertension: do gene therapies have translational values?
Roxane Paulin, Marjorie Barrier, Sebastien Bonnet
Editorial: Clinical Investigation
-
New therapeutics for pulmonary arterial hypertension: do gene therapies have translational values?
Roxane Paulin, Marjorie Barrier, Sebastien Bonnet
Editorial: Clinical Investigation